Pharmaceutical Drugs

CAMDEN, NJ, Aug. 1, 2017 – A Japanese pharmaceutical company, Daiichi Sankyo, will pay $300 million to settle thousands of federal and state court lawsuits over its top-selling blood pressure drugs, Benicar, Benicar HCT, Azor and Tribenzor, according to an announcement made today by the lead Plaintiffs’ lawyers in U.S. federal district court.

In a new safety alert, the FDA is warning of a dangerous risk of leg and foot amputations stemming from canagliflozin, the active ingredient in both Invokamet and Invokana, two widely used diabetes drugs. The FDA released the safety alert after reviewing the final results from two different clinical trials that looked at the drugs and their long-lasting effects over a large sample of patients suffering from type 2 diabetes.

The team at Pendley, Baudin & Coffin is currently investigating cases involving injury to infants and children from Hyland’s homeopathic teething tablets and gels.

PBC is pleased to announce that its own Chris Coffin has been appointed to the Plaintiffs' Steering Committee that will take the lead on all federal Taxotere litigation for plaintiffs throughout the U.S.

Taxotere, a chemotherapy drug manufactured by Sanofi-Aventis and primarily used to treat breast cancer, is linked to permanent hair loss or "alopecia" in women who were undergoing treatment for breast cancer.

Law360, New York (May 9, 2016, 4:05 PM ET) -- Health care fund providers seeking to recover money lost because of Forest Laboratories' allegedly fraudulent promotion of its drugs in treating pediatric depression pressed a Massachusetts federal judge to certify their portion of the multidistrict litigation as a class, saying previous court rulings and

Chris Coffin appointed Co-Lead Counsel and a member of the Plaintiffs' Executive Committee in the Benicar (Olmesartan) Products Liability Litigation.